SDC1 and plasma cell myeloma: These cells have clonogenic potential in vitro and, when engrafted into immunodeficienct/nonobese diabetes (SCID/NOD) mice, can initiate de novo myeloma lesions of bulk of CD138+ cells in both primary and secondary transplant assays.